Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Synergy study with chemotherapeutic agents is a common in vitro strategy in the search for effective cancer therapy. For non-chemotherapeutic agents, efficacious synergistic effects are uncommon. Here, we have examined two non-chemotherapeutic agents for synergistic effects: lovastatin and Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL) for synergistic effects; on three human malignant glioblastoma cell lines, M059K, M59J, and A172. Cells treated with lovastatin plus TRAIL for 48 h showed 50% apoptotic cell death, whereas TRAIL alone (1,000 ng/ml) did not, suggesting that lovastatin sensitized the glioblastoma cells to TRAIL attack. Cell cycle analysis indicated that lovastatin increased G(0)-G(1) arrest in these cells. Annexin V study demonstrated that apoptosis was the predominant mode of cell death. We conclude that the combination of lovastatin and TRAIL enhances apoptosis synergistically. Moreover, lovastatin sensitized glioblastoma cells to TRAIL, suggesting a new strategy to treat glioblastoma.
著者Chan DYL, Chen GG, Poon WS, Liu PC
期刊名稱Journal of Neuro-Oncology
出版年份2008
月份2
日期1
卷號86
期次3
出版社SPRINGER
頁次273 - 283
國際標準期刊號0167-594X
電子國際標準期刊號1573-7373
語言英式英語
關鍵詞apoptosis; glioblastoma; lovastatin; Tumor Necrosis Factor (TNF)-related apoptosis-inducing ligand (TRAIL)
Web of Science 學科類別Clinical Neurology; CLINICAL NEUROLOGY; Neurosciences & Neurology; Oncology; ONCOLOGY

上次更新時間 2021-15-01 於 23:56